Galmed Pharmaceuticals Ltd. (GLMD)
- Previous Close
0.3940 - Open
0.3800 - Bid --
- Ask --
- Day's Range
0.3702 - 0.3900 - 52 Week Range
0.2600 - 5.6300 - Volume
30,156 - Avg. Volume
189,340 - Market Cap (intraday)
2.334M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5000 - Earnings Date May 30, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
www.galmedpharma.comRecent News: GLMD
Performance Overview: GLMD
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLMD
Valuation Measures
Market Cap
2.33M
Enterprise Value
-10.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.17
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.22%
Return on Equity (ttm)
-50.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.91M
Diluted EPS (ttm)
-2.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.64M
Total Debt/Equity (mrq)
0.29%
Levered Free Cash Flow (ttm)
-3.63M
Research Analysis: GLMD
Company Insights: GLMD
GLMD does not have Company Insights